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DR. JOHN KERSEY RECEIVES
LIFETIME ACHIEVEMENT AWARD
A pioneer in blood and marrow
transplantation who has played a ma-
jor role in current understanding of
the cellular and molecular basis of
childhood leukemia has been named
recipient of the 2003 ASBMT Lifetime
Achievement Award. John H. Kersey,
MD, director of the University of Min-
nesota Cancer Center, Minneapolis,
received the award at the ASBMT an-
nual meeting in Keystone, Colo.
“Dr. Kersey has been one of the
leaders in our field, especially in the
translational science of human acute
leukemia,” ASBMT president John
Wingard, MD, said in presenting the
award. “His lab was one of the first in
the country to use monoclonal anti-
bodies to treat leukemia.”
The annual Lifetime Achievement
Award is supported by a grant from
Pharmacia Corporation.
In 1975, Dr. Kersey and colleagues
performed the world’s first successful
bone marrow transplant for lym-
phoma. The patient was a 16-year-
old boy with a rare form of cancer
called Burkitt’s lymphoma, which at
the time was a fatal disease. The “boy”
is now a husband and father in his
40s and is doing well.
Always at the forefront of under-
standing the role of stem cell trans-
plants for leukemia, Dr. Kersey was
among the first to recognize that leu-
kemia represents distinct stages of
normal lymphocytes, including T
cells. His studies helped explain the
mechanisms of basic lymphocyte
function and defined the role of total
lymphoid irradiation and T-cell deple-
tion for graft-versus-host disease. He
was a force behind the creation of
the University of Minnesota Cancer
Center, which was established in
1991 and designated a comprehen-
sive cancer center by the National
Cancer Institute in 1998.
A graduate of Dartmouth College,
Dr. Kersey earned his medical degree
in 1964 at the University of Minnesota
School of Medicine. After an intern-
ship he joined the U.S. Army and
served in Kenya, Pakistan, Turkey,
and California. From 1968 to 1972
he completed residencies in pathol-
ogy, immunology, oncology, and pe-
diatrics at the University of Minnesota
and then joined the faculty where he
has remained ever since. He was di-
rector of the Bone Marrow Transplant
Program at the university from 1974
to 1995, the year he was appointed
director of the cancer center.
Dr. Kersey was elected president of
the International Society of Experimen-
tal Hematology in 1995–1996, and of
the American Society for Blood and
Marrow Transplantation in 1997–1998.
Dr. Kersey is an author of nearly
500 articles in medical journals such
as the New England Journal of Med-
icine, Lancet, Science, Nature, Jour-
nal of the American Medical Associa-
tion, Annals of Internal Medicine, and
Cancer. He is an associate editor of
Blood, the Journal of Clinical Immu-
nology, and Cancer Research. He
spends about 20 percent of his time
seeing patients—children with leuke-
mia or lymphoma.
DIFFERENTIATION, DESTRUCTION
OF CANCER CELLS IS GOAL OF
ASBMT/ROCHE NEW INVESTIGATOR
Among the new investigators con-
ducting research under an ASBMT
grant is Subramaniam Malarkannan,
PhD, assistant professor of medicine
at the Medical College of Wisconsin,
Milwaukee. He is a recipient of the
ASBMT/Roche New Investigator
Award—a $25,000-per-year grant
supported by an unrestricted educa-
tion grant from Roche Pharmaceuti-
cals.
Chosen from among competing re-
search proposals, Dr. Malarkannan’s
research concerns the differentiation
and destruction of cancer cells. His
objective is to determine whether
cells in the body’s immune system can
recognize minor histocompatibility
antigen protein molecules on tumor
cells and use them to target tumor
cells for destruction. Using mouse
models, he has identified four novel
minor histocompatibility antigens that
are candidates for targeted tumor kill-
ing. Because similar antigens are
found on human cells, the research
could be translated for clinical appli-
cations.
Dr. Malarkannan is using molecular
techniques to study the minor histo-
compatibility antigens and determine
their tissue distribution on both nor-
mal and leukemia cells. Eventually, he
hopes to design treatment strategies
using specific immune cells, such as T
lymphocytes and natural killer cells, to
recognize and kill leukemia cells with-
out causing damage to healthy nor-
mal cells. This form of adoptive cellu-
lar immunotherapy would be done in
combination with a blood or marrow
stem cell transplant.
Dr. Malarkannan has been a mem-
ber of the staff in the Division of Neo-
plastic Diseases at the Medical Col-
lege of Wisconsin since March 2000.
He earned a doctorate in immunol-
ogy in 1992 at Madurai Kamaraj Uni-
versity in Madurai, India, and com-
pleted a postdoctoral fellowship in
immunology in 1998 at the University
of California, Berkeley. He holds mas-
ter’s degrees in energy sciences from
Madurai Kamaraj University and in zo-
ology from The American College in
Madurai.
Funded by an unrestricted educa-
tional grant from Roche Pharmaceu-
ticals, the renewal two-year grant en-
courages clinical and laboratory
research by new investigators in the
field of blood and marrow transplan-
tation. Applicants must be an instruc-
tor or assistant professor at the junior
faculty level.
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